1. Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population

   • Ying Wei
   • Xiaolin Wang
   • Xinhan Zhao

   Review 23 June 2020 Pages: 1 - 8

2. A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer

   • Rachel Starkings
   • Valerie Shilling
   • Lesley Fallowfield

   Review Open access 23 June 2020 Pages: 9 - 21

   

3. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

   • Michelle D. Hackshaw
   • Heather E. Danysh
   • Charles A. Powell

   Review Open access 26 June 2020 Pages: 23 - 39

   

4. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer

   • Yoshiya Horimoto
   • Noriko Sasahara
   • Mitsue Saito

   Preclinical study 22 June 2020 Pages: 41 - 48

   

5. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer

   • Rashmi Verma
   • Andrew M. Hanby
   • Thomas A. Hughes

   Preclinical study Open access 23 June 2020 Pages: 49 - 59

   

6. Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer

   • Fang-Ming Chen
   • Li-Ju Huang
   • Ming-Feng Hou

   Preclinical study 29 June 2020 Pages: 61 - 70

   

7. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA

   • Xiaowei Yang
   • Lu Zhao
   • Benzhong Wang

   Preclinical study 29 June 2020 Pages: 71 - 82

   

8. Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema

   • Paula M. C. Donahue
   • Rachelle Crescenzi
   • Manus J. Donahue

   Preclinical study 29 June 2020 Pages: 83 - 94

   

9. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers

   • Dingxie Liu

   Preclinical study 29 June 2020 Pages: 95 - 105

   

10. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

    • Ahrong Ham
    • Min Hwan Kim
    • Joohyuk Sohn

    Clinical trial 23 June 2020 Pages: 107 - 116

    

11. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study

    • Hadeer G. Khalefa
    • May A. Shawki
    • Lamia M. El Wakeel

    Clinical trial 29 June 2020 Pages: 117 - 125

    

12. Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy

    • George E. Naoum
    • Oluwadamilola T. Oladeru
    • Alphonse G. Taghian

    Clinical trial 30 June 2020 Pages: 127 - 136

    

13. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer

    • Vincent Walter
    • Chiara Fischer
    • Markus Wallwiener

    Clinical trial Open access 01 July 2020 Pages: 137 - 144

    

14. Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery

    • Elyse LeeVan
    • Be Thi Ho
    • Jeannie Shen

    Clinical trial 01 July 2020 Pages: 145 - 151

15. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study

    • Sixten Harborg
    • Uffe Heide-Jørgensen
    • Signe Borgquist

    Epidemiology Open access 22 June 2020 Pages: 153 - 160

    

16. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score

    • Stephanie Robertson
    • Balazs Acs
    • Johan Hartman

    Epidemiology Open access 22 June 2020 Pages: 161 - 175

    

17. Cardiovascular mortality and morbidity burden in successive and age pre-stratified case–control cohorts of breast cancer women. A population-based study

    • Lidia Staszewsky
    • Fabio Robusto
    • Roberto Latini

    Epidemiology 25 June 2020 Pages: 177 - 188

18. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management

    • Marianna Cavazza
    • Helen Banks
    • Francesco Longo

    Epidemiology 26 June 2020 Pages: 189 - 199

    

19. Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data

    • Melissa K. Accordino
    • Jason D. Wright
    • Dawn L. Hershman

    Epidemiology 26 June 2020 Pages: 201 - 211

    

20. Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China

    • Jing Yao
    • Yanfang Liu
    • Jing Cheng

    Epidemiology 27 June 2020 Pages: 213 - 216

    

21. Association between selenium intake and breast cancer risk: results from the Women’s Health Initiative

    • Dan Guo
    • Michael Hendryx
    • Juhua Luo

    Epidemiology 30 June 2020 Pages: 217 - 226

    

22. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

    • Diana G. Wang
    • Dulce M. Barrios
    • Mario E. Lacouture

    Epidemiology 29 June 2020 Pages: 227 - 237

    

23. Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer

    • Marta Perachino
    • Francesca Poggio
    • Matteo Lambertini

    Letter to the Editor 28 June 2020 Pages: 239 - 240

24. A case for Tamoxifen with ovarian function suppression

    • Pallavi Kopparthy
    • Karen Daily

    Letter to the Editor 29 June 2020 Pages: 241 - 242